SCHEMBL435378

SCHEMBL435378

O=C(O)CCC1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
EPHX2 P34913 10/20 0.51
CYP2C8 P10632 1/20 0.51
CYP2C9 P11712 2/20 0.48
CNR1 P21554 1/20 0.47
SLC6A4 P31645 3/20 0.43
SLC6A3 Q01959 3/20 0.43
HSD11B1 P28845 1/20 0.43
CYP3A4 P08684 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
SLC6A2 P23975 2/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8484287 0.83 MAOA (0.50) EPHX2CYP2C8CNR1
SCHEMBL31650281 0.82 ALDH1A1 (0.42) ALDH1A1EPHX2CYP2C8HSD11B1FFAR4
SCHEMBL7177946 0.81 ALDH1A1 (0.61) ALDH1A1EPHX2CNR1SLC6A4SLC6A3
SCHEMBL10726449 0.77 SLC6A4 (0.48) ALDH1A1EPHX2CNR1SLC6A4SLC6A3
SCHEMBL31650456 0.77 DRD2 (0.44) ALDH1A1EPHX2CNR1SLC6A4SLC6A3
SCHEMBL18440285 0.76 EPHX2 (0.52) ALDH1A1EPHX2CYP2C8SLC6A4SLC6A3
SCHEMBL8485828 0.76 DPP4 (0.53) ALDH1A1EPHX2CYP2C8SLC6A4SLC6A3
SCHEMBL8506344 0.76 HSD11B1 (0.41) ALDH1A1EPHX2CYP2C8CYP2C9HSD11B1
SCHEMBL436643 0.75 DPP4 (0.52) ALDH1A1EPHX2CYP2C8SLC6A4SLC6A3
SCHEMBL624643 0.75 HSD11B1 (0.63) ALDH1A1EPHX2CYP2C8CNR1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 WO disclosed
EP-2595969-B1 Substituted 3-phenyl-1,2,4-oxadiazole compounds BRISTOL MYERS SQUIBB CO (US) 2015-04-22 EP disclosed
CN-103124727-B Substituted 3-phenyl-1,2,4-oxadiazole compounds BRISTOL MYERS SQUIBB CO 2015-03-25 CN disclosed
US-8822510-B2 Substituted 3-phenyl-1,2,4-Oxadiazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-02 US disclosed
US-20130158001-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUBIB COMPANY 2013-06-20 US disclosed
EP-2595969-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS Bristol-Myers Squibb Company (US) 2013-05-29 EP disclosed
CN-103124727-A Substituted 3-phenyl-1,2,4-oxadiazole compounds BRISTOL MYERS SQUIBB CO 2013-05-29 CN disclosed
WO-2012012477-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158001-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS S1PR1, S1PR3, S1PR2 ALDH1A1 1493/4885EPHX2 1646/4885CYP2C8 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.